^
    1m
    PALVEN: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Peter MacCallum Cancer Centre, Australia | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2)
    |
    ER positive • HER-2 negative • BCL2 positive • HER-2 negative + ER positive
    |
    Venclexta (venetoclax) • Ibrance (palbociclib) • letrozole
    1m
    Associations between BCL-2 expression and different histopathological prognostic factors in different molecular subtypes of invasive breast carcinoma of no special type. (PubMed, Histol Histopathol)
    BCL-2 expression in IBC; NST has different prognostic effects depending on the molecular subtype of the cancer. In cancers with a HER2-enriched phenotype, BCL-2 expression was a marker of poor prognosis, while in cancers with a hormone receptor-positive phenotype, BCL-2 expression had a better prognostic impact.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HR positive • HER-2 negative • BCL2 expression • BCL2 positive
    2ms
    Expression of Axl Receptor Tyrosine Kinase and Its Association With Ki-67 Proliferation Marker, BCL-2 Anti-apoptotic Protein, Hormone Receptor Status, and HER2/Neu Status in Breast Cancer Among Women From Duhok, Iraq. (PubMed, Cureus)
    Conclusion Axl receptor was not associated with all of the clinicopathological variables, the expression values were high in malignant tumors in comparison with the benign tumors, and it was found that Axl receptor expression was associated with low/intermediate grade, which is considered a favorable prognostic factor. Although Axl receptor expression was previously linked with proliferation and invasiveness in BC, its association with the Ki-67 proliferation marker and BCL-2 anti-apoptotic protein was not observed.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2) • AXL (AXL Receptor Tyrosine Kinase)
    |
    BCL2 positive
    2ms
    Comparison of B-cell lymphoma 2 (BCL-2) expression in disordered proliferative endometrium and simple endometrial hyperplasia. (PubMed, Rev Esp Patol)
    BCL-2 expression is observed with a relatively similar frequency in DPE and SEH samples, and it is probably under the control of oestrogen hormone as the main factor involved in the pathogenesis of these lesions.
    Clinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • BCL2 positive
    3ms
    BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. (PubMed, J Clin Invest)
    We provide evidence that BCL2 expression is regulated by DNA methylation, associated with epithelial-mesenchymal transition, and increased by the neuronal transcription factor ASCL1. Finally, BCL2 inhibition had antitumor activity in some, but not all, BCL2-positive PC models, highlighting the need for combination strategies to enhance tumor cell apoptosis and enrich response.
    Journal • IO biomarker • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    BCL2 expression • BCL2 positive • AR expression • AR negative
    3ms
    Clinico-pathological association of BCL2 in invasive breast carcinoma: A study from tertiary care health centre in Northern India. (PubMed, Indian J Pathol Microbiol)
    Expression of Bcl-2, an antiapoptotic protein, is associated with low-grade, slowly proliferating, luminal A-type BC. IHC analysis of Bcl-2 is simple, inexpensive, readily available test to stratify early-stage hormone-positive patients who can be included in clinical trials for Bcl-2 inhibitors.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • BCL2 positive
    3ms
    Evaluation of Immunohistochemical Marker Bcl-2 in Epithelial Dysplasia and Squamous Cell Carcinoma of the Oral Cavity. (PubMed, Cureus)
    In poorly differentiated oral squamous cell carcinoma Bcl-2 positivity was high and low in well-differentiated oral squamous cell carcinoma. Bcl-2 expression was higher in severe dysplasia compared to moderate dysplasia, which may indicate aggressive behaviour of tumour in poorly differentiated oral squamous cell carcinoma and severe dysplasia.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • BCL2 positive
    7ms
    Primary Pulmonary Diffuse Large B-cell Lymphoma Mimics Advanced Lung Cancer:Report of a Case (PubMed, Kyobu Geka)
    We report a case of primary pulmonary DLBCL caused by methotrexate-associated lymphoproliferative disorder (MTX-LPD)...MTX-LPD was suspected, and discontinuation of the drug resulted in subsequent shrinkage of the residual tumor. If the diagnosis cannot be made by transbronchoscopic biopsy of an expanding nodule shadow, aggressive surgical diagnosis should be considered.
    Journal • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • BCL2 positive
    |
    methotrexate
    8ms
    Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. (PubMed, Blood Adv)
    Because continuous inhibition of BCL-XL causes thrombocytopenia, we proposed and tested an interrupted 4 days ON / 3 days OFF treatment regimen, which retained the desired anti-tumor synergy with manageable platelet toxicity. The proposed VEN and A1155463 combination represents an innovative chemotherapy-free regimen with significant preclinical activity across diverse BCL2-positive hematologic malignancies irrespective of the BCL1L11/BIM status.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BCL2L11 (BCL2 Like 11)
    |
    BCL2 expression • BCL2 positive • BCL2L11 deletion
    |
    Venclexta (venetoclax)
    10ms
    Intrathyroidal thymic carcinoma not so indolent a neoplasm? (PubMed, Indian J Pathol Microbiol)
    The classically described ivory-white gross appearance of the tumor, histomorphology of thick bands dividing the tumor into lobules, squamous cell differentiation, tight whorls of cells resembling Hassall's corpuscle, and areas showing dense lymphocytic infiltration, together with an immunoprofile of CD5, Ckit, Tumor protein 63 (p63), and B-cell lymphoma 2 gene (bcl2) positivity, helped in diagnosing this rare entity. Though classically ITC is said to have a good prognosis, cases with spread to adjacent organs and lymph node metastasis may not have an indolent course.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule) • TP63 (Tumor protein 63)
    |
    BCL2 positive
    10ms
    FIL_GAZEBO: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (clinicaltrials.gov)
    P3, N=190, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 positive
    |
    Gazyva (obinutuzumab)
    11ms
    Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning. (PubMed, Diagn Pathol)
    We conclude that proportion of positive stains can be regressed using attention-based multiple instance learning, that these models generalize well to whole slide images, and that our models can provide non-inferior stratification of progression-free survival outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 positive • MYC positive
    1year
    Analysis of 9 cases of pediatric-type follicular lymphoma (PubMed, Zhonghua Er Ke Za Zhi)
    PTFL is mainly characterized by adolescent male onset, with early clinical manifestations and pathological manifestations of high-level histological status, high proliferation index, and lack of t (14; 18)/Bcl-2 translocation and Bcl-2 expression. It is mainly treated by localized surgical excision and has a good prognosis.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • BCL2 expression • BCL2 positive • MYC translocation • MYC negative • BCL2 translocation
    1year
    Correlation of Flow Cytometric BCL2 and MCL1 Expression with Cytogenetic Characteristics and Outcome in Multiple Myeloma (ASH 2023)
    Our study demonstrates an objective assessment of BCL2 and MCL1 expression by FCM. BCL2 PC/T,MCL1 PC/T and BCL2 PC /MCL1 PC were significantly higher in myeloma cells compared to non-clonal PCs. Low MCL1 expression or high BCL2/MCL1 ratio was associated with IGH: : CCND1; while strong MCL1 and low BCL2/MCL1 ratio was most frequent in 1q21 amplification.
    IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • FGFR3 (Fibroblast growth factor receptor 3) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BCL2L2 (BCL2 Like 2) • BCL2L10 (BCL2 like 10) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 deletion • BCL2 expression • BCL2 positive • MCL1 expression
    |
    Venclexta (venetoclax)
    1year
    Clinical pathological characteristics analysis of ocular adnexal follicular lymphoma (PubMed, Zhonghua Yan Ke Za Zhi)
    It can involve the lacrimal gland, extraconal muscles, lacrimal sac, and conjunctiva. Patients generally have a favorable prognosis.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    BCL2 expression • BCL2 positive
    1year
    CD23 positive, BCL2 rearrangement-negative germinal centre lymphomas (PubMed, Pathologie (Heidelb))
    Genetically, this lymphoma group is characterised by a high rate of either STAT6 or SOCS1 mutations.The ICC classification took this development into account by introducing the provisional entity CD23 positive, BCL2 rearrangement-negative germinal centre lymphoma. Further studies must now show how exactly this entity can be defined (combination of morphology, immunohistochemical phenotype, focus on genetic alterations) in order to pave the way towards a uniform classification and a better clinical characterisation of these cases - especially with regard to possible new therapeutic treatment options.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    BCL2 positive • BCL2 rearrangement • SOCS1 mutation • BCL2 translocation
    1year
    Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study (ASH 2023)
    Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy is the standard first-line treatment of DLBCL...Previous study has showed that ibrutinib combined with R-CHOP had improved event free survival (EFS) compared with placebo plus R-CHOP in non-GCB DLBCL patients with BCL2 and MYC co-expression (Johnson et al., Blood 2019)...Conclusions At the time of data cut-off 30 Jun 2023, 6 cycles of zanubrutinib combined with R-CHOP regimen was well tolerated and showed a promising response result in untreated non-GCB double-expression DLBCL patients. The study is ongoing and further results will be continuously released.
    Clinical • P2 data • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • MYC expression • BCL2 expression + MYC expression • BCL2 positive • MYC positive • MYC expression + BCL2 expression
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • vincristine • prednisone
    1year
    Pre-Clinical Activity of Navitoclax in TCR-Driven and Non-ALCL Mature T-Cell Lymphomas (ASH 2023)
    In an effort to further confirm these results, and examine the extent to which peptide-based BH3 profiling predicts sensitivity to selective BH3 mimetics in MTCL, cell lines were treated with venetoclax, A1155463 (a BCL-xL selective antagonist), navitoclax (a BCL-2/BCL-xL antagonist), or S63845 (MCL-1 antagonist), and cell viability determined. These findings suggest that BCL-xL is a therapeutic vulnerability for MTCL subsets, particularly non-ALCL subtypes that are TCR dependent, and provide a robust pre-clinical rationale for future studies investigating navitoclax in these lymphomas.
    Preclinical • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CD28 (CD28 Molecule) • BCL2L2 (BCL2 Like 2)
    |
    BCL2 overexpression • BCL2 expression • BCL2 positive • MCL1 expression
    |
    Venclexta (venetoclax) • navitoclax (ABT 263) • S63845
    1year
    Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML (ASH 2023)
    Genotype and phenotype both modulate VEN sensitivity in AML. Myeloid differentiation is associated with increased alternative anti-apoptotic protein expression and VEN resistance irrespective of genotype; however certain mutations (i.e., IDH1/2) may retain prognostic significance independent of myeloid differentiation. Given both factors influence VEN sensitivity, prognostic models incorporating AML phenotype and genotype may further improve risk stratification and predict response to VEN based therapy in AML.
    IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • IKZF1 (IKAROS Family Zinc Finger 1) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • CD14 (CD14 Molecule) • BCL2A1 (BCL2 Related Protein A1) • GATA2 (GATA Binding Protein 2) • ITGAM (Integrin, alpha M) • PHF6 (PHD Finger Protein 6) • CLEC7A (C-Type Lectin Domain Containing 7A) • GATA1 (GATA Binding Protein 1)
    |
    NPM1 mutation • BCL2 expression • BCL2 positive • IDH wild-type
    |
    Venclexta (venetoclax)
    1year
    Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma (ASH 2023)
    Background: The Phase II CAVALLI study assessed the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (Ven; 800mg for 10 days [Ds]) + rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O) and prednisolone (P; R-CHOP), for first line treatment of diffuse large B-cell lymphoma (DLBCL)...In the Phase III POLARIX study, polatuzumab vedotin (Pola)-R-CHP had a prolonged PFS vs R-CHOP, establishing Pola-R-CHP as standard of care for untreated DLBCL (Tilly et al... Ven 800mg/D for 5 Ds/cycle + Pola-R-CHP has been determined as the RP2D; early results show acceptable safety and promising efficacy for untreated BCL-2 IHC+ DLBCL. High CR rates were observed across all cohorts at EOT, including pts with DHL/THL. Updated results, including circulating tumor DNA, will be presented.
    Clinical • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 overexpression • BCL2 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Polivy (polatuzumab vedotin-piiq)
    1year
    A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis – a GLA/ Dshnhl and Lysa Collaboration (ASH 2023)
    Deleting the number of extranodal sites and adding BCL2 expression to the original IPI factors as the only readily available biologic marker allows building an IPI model which effectively separates IPI 3 pts in 2 groups with significantly different prognosis. Restricting eligibility for future clinical trials to DLBCL pts with IPI 3 (and IPI 4) who are BCL2-pos. may help to avoid overtreatment of pts well treated with R-CHOP and at the same time better select pts representing a group with truly unmet medical need who are most likely to benefit from experimental therapies.
    Clinical • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • MYC expression • BCL2 expression + MYC expression • BCL2 positive • MYC rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab)
    1year
    Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review. (PubMed, World J Surg Oncol)
    We reported a relatively rare PB-DLBCL in a male, non-GBC phenotype, dual-expression type. It is worth mentioning that this case had IgH/BCL6 fusion, nonsense mutations in TNFAIP3, frameshift mutations in PRDM1, and missense mutations in CREBBP, DTX1, and FOXO1. To the best of our knowledge, this case is the first report of genomic mutational profiles of PB-DLBCL in males.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CREBBP (CREB binding protein) • TNFAIP3 (TNF Alpha Induced Protein 3) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • PRDM1 (PR/SET Domain 1)
    |
    CD20 positive • BCL2 positive • CREBBP mutation • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • PRDM1 mutation • BCL6 positive • BCL6 fusion
    |
    Rituxan (rituximab) • cytarabine • Inokai (orelabrutinib)
    1year
    Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms. (PubMed, Leukemia)
    In BCL2 + FL mutations in KMT2D, BCL2, ABL2, IGLL5 and ARID1A were enriched, while STAT6 mutations more frequently occurred in BCL2- FL. Although the landscape of lFL and sFL showed overlapping features, molecular profiling revealed novel insights and identified gains in 18q21 as prognostic marker in lFL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • KMT2D (Lysine Methyltransferase 2D) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase) • STAT6 (Signal transducer and activator of transcription 6) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)
    |
    ARID1A mutation • KMT2D mutation • BCL2 positive • BCL2 translocation
    1year
    Panfollicular carcinoma with perineural invasion (ASDP 2023)
    Perineural invasion has not been described previously, and can be a clue to the malignant nature of such tumors. Poster type: Poster Defense
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    BCL2 positive • CTNNB1 expression
    1year
    Pathogenesis of Gastrointestinal Follicular Lymphomas: Consideration Based on Histopathology and Endoscopic Findings. (PubMed, Am J Surg Pathol)
    These differences might be attributed to variations in each GI site's mucosal structure and the neoplastic follicles' size. Due to its characteristic structure, very small classic FLs might be detectable mainly in the small intestine.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MME (Membrane Metalloendopeptidase)
    |
    BCL2 positive
    over1year
    FIL_GAZEBO: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (clinicaltrials.gov)
    P3, N=190, Not yet recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Dec 2030 --> Apr 2031 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Dec 2030 --> Apr 2031
    Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 positive • BCL2 rearrangement
    |
    Gazyva (obinutuzumab)
    over1year
    Diagnostic Pitfall of p16 Interpretation in Tubal Metaplasia Versus Endocervical Adenocarcinoma In Situ (CAP 2023)
    When minimal tissue is present for examination, a diffuse p16 positivity can lead to a misdiagnosis of a malignant lesion, leading to significant morbidity for the patient. p16 immunohistochemical staining in glandular tissue, especially in smaller specimens showing focal diffuse positivity, should be interpreted with caution, especially since tubal metaplasia can also morphologically mimic a rare variant of endocervical AIS, tubal/ciliated AIS.
    IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2)
    |
    ER positive • BCL2 positive
    over1year
    Adenoid Cystic (Basal Cell) Carcinoma of the Prostate: A Series of 4 Cases (CAP 2023)
    BCC is a rare subtype of prostate cancer with a spectrum of clinicopathologic characteristics that can occur in association with conventional adenocarcinoma. Our small case series confirms that it is a potentially aggressive neoplasm with metastatic potential and can result in poor outcomes.
    Clinical
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 positive
    over1year
    Divergent evolution of metachronous follicular lymphoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue from a common precursor. (PubMed, J Pathol)
    © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 positive
    over1year
    High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy. (PubMed, Cells)
    Venetoclax targeting of BCL-2 increased while the spautin-1-mediated inhibition of BECLIN-1-dependent autophagy reversed doxorubicin sensitivity in the former and in the latter, respectively. Notably, patients with high BECN1 expression displayed longer survival. Our data reveal, for the first time, that the modulation of BECLIN-1-dependent autophagy influences the prognosis of DLBCL patients and provide a mechanistic explanation supporting the therapeutic use of drugs that, by stimulating autophagy, can sensitize lymphoma cells to chemotherapy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • BECN1 (Beclin 1)
    |
    BCL2 overexpression • BCL2 expression • BCL2 positive • HIF1A expression
    |
    Venclexta (venetoclax) • doxorubicin hydrochloride
    over1year
    Protective effects of Althaea officinalis L. extract against N-diethylnitrosamine-induced hepatocellular carcinoma in male Wistar rats through antioxidative, anti-inflammatory, mitochondrial apoptosis and PI3K/Akt/mTOR signaling pathways. (PubMed, Food Sci Nutr)
    Therefore, ALOF was able to modulate the proliferation of cancer cells and protect normal cells through the regulation of Bax/Bcl-2/p53 and PI3K/Akt/mTOR signaling pathways. It seems that ALOF can be used as a prodrug or complementary treatment in the protection of hepatocytes in induced damages caused by carcinogens.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • CAT (Catalase) • CRP (C-reactive protein)
    |
    BCL2 positive
    over1year
    DOUBLE-HIT LYMPHOMA TRANSFORMATION DIAGNOSED VIA ENDOBRONCHIAL MASS IN THE PRESENCE OF COVID INFECTION COMPLICATIONS (CHEST 2023)
    This case report is unique in diagnosis process, pathology and final treatment plan. The patient was initially diagnosed with follicular lymphoma, but was complicated by COVID-19 infection, leading to bronchoscopy, which yielded an obstructing endobronchial mass. Biopsy returned the transformation into aggressive double hit lymphoma, and a new direction for chemotherapy was needed.
    IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC expression • BCL2 positive • MYC rearrangement • BCL2 rearrangement
    over1year
    A B-Wildering Case of Gastrointestinal Bleeding (ACG 2023)
    Case Description/ A 63-year-old male with a history of coronary artery disease, on aspirin and clopidogrel, presented to the advanced endoscopy clinic for evaluation of GI bleeding with associated anemia...Numerous mitotic figures and apoptotic debris were also noted. (c) The large atypical lymphocytes express CD20 (10x objective) staining, consistent with B cell origin.
    Clinical
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 expression • BCL2 positive • MYC positive
    |
    Cologuard®
    over1year
    High Grade B-Cell Lymphoma, Not Otherwise Specified: A Rare Case of Primary Gastric Lymphoma (ACG 2023)
    Treatment was initiated with pulse-dose corticosteroids and intrathecal methotrexate and continued etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) per outpatient oncology. (C) Gastric mucosa with diffuse infiltrate of abnormal large lymphocytes. (D) Ki67, proliferation antigen, positive in almost 100% of cells, compatible with high grade lymphoma.
    Clinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL2 positive • MYC rearrangement • MYC translocation
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone
    over1year
    Colonic Small Lymphocytic Lymphoma Presenting as Lower Gastrointestinal Bleeding (ACG 2023)
    Oral chemotherapy ibrutinib was started, with plans for close monitoring of liver functions given her history of alcohol use...Frequent monitoring for colorectal cancer and surveillance for disease recurrence should be considered for these patients. Figure: Figure 1: Colonoscopy showing sessile polyps in the transverse colon (circled)
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive • BCL2 positive
    |
    Imbruvica (ibrutinib)
    over1year
    The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma. (PubMed, Clin Exp Med)
    Surgical resection could predict favorable PFS but not OS. Moreover, BCL2 and PD-L1 expression can be employed as prognostic markers in these patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2)
    |
    PD-L1 expression • BCL2 positive
    over1year
    Prognostic influences of B-cell lymphoma 2-positive expression on late recurrence in breast cancer. (PubMed, Ann Surg Treat Res)
    Our result showed that prognosis was better in BCL2-positive patients compared to BCL2-negative patients at late recurrence. We suggested that BCL2 expression could be used as a marker to help determine additional adjuvant therapy or extended hormone therapy in hormone-dependent breast cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • BCL2 positive
    over1year
    Impact of the gating strategy for Ki-67 and Bcl-2 on the determination of proliferation and anti-apoptosis data by flow cytometry in non-malignant bone marrow aspirates and aspirates from patients with myeloid malignancies. (PubMed, Data Brief)
    The Ki-67 proliferation index and Bcl-2 anti-apoptotic index may potentially be used for classification of MDS and AML based on supervised machine learning algorithms, while unsupervised machine learning can be deployed at the level of single cells to potentially distinguish non-malignant from malignant cells in the identification of minimal residual disease. Therefore, the present dataset may be of interest for internist-hematologists, immunologists with affinity for hemato-oncology, clinical chemists with sub-specialization of hematology and researchers in the field of hemato-oncology.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule)
    |
    BCL2 positive • CD34 positive